Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Physician's Choice in HR+/HER2- Breast Cancer
NCT06339281Phase 2Not yet recruiting
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Rivoceranib in breast cancer. Planned start May 2024; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06339281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06339281.